SEHK:6990
SEHK:6990Biotechs

A Look At Sichuan Kelun Biotech (SEHK:6990) Valuation After New Breakthrough Therapy And IND Approvals

Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) has drawn fresh investor attention after China’s regulator granted Breakthrough Therapy Designation for sacituzumab tirumotecan with pembrolizumab in first line PD-L1-positive lung cancer, alongside IND approval for SKB105 in advanced solid tumors. See our latest analysis for Sichuan Kelun-Biotech Biopharmaceutical. The latest regulatory milestones appear to be feeding into strong momentum, with a 1-day share price return of 2.64%, a 7-day...